Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: a retrospective study in UK primary care
Open accessAbstract
Objective Type 2 diabetes is a chronic condition that continues to increase in prevalence in the UK. Incretin-based therapies, including liraglutide and sitagliptin, provide adequate blood glucose control. Clinical trials have shown that liraglutide offers greater glycaemic control and body weight reduction in comparison to sitagliptin. We aimed to assess the effectiveness of liraglutide and sitagliptin in routine clinical practice. Materials and methods We designed and conducted a retrospective database analysis in primary care using the Clinical Practice Research Datalink in the UK. Patients aged ≥ 18 years, diagnosed with type 2 diabetes and prescribed liraglutide or sitagliptin between July 2009 and July 2012, were included in the study. Glycaemic and weight control were investigated 6 months after treatment initiation. Results A total of 287 liraglutide and 2781 sitagliptin patients were identified. Compared with sitagliptin, liraglutide recipients had greater reductions in HbA1c (%) (-0.90 vs. -0.57, p Conclusions Clinical trials show superior glycaemic control and weight reduction with liraglutide compared with sitagliptin. This finding is reflected in routine clinical practice in the UK.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Past GLP-1 RA studies reported mean weight change ranging from −1.0 kg to −3.78 kg over 6-12 months.
“In these studies, mean weight change ranged from −1.0 kg to −3.78 kg over 6–12 months.”
From Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK (2022) · cites this paper as [20]
The few studies that have evaluated real-world effectiveness of GLP-1 RAs have yielded inconsistent results.
“The few studies that have evaluated real-world effectiveness of GLP-1 RAs have yielded inconsistent results.”
From Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK (2022) · cites this paper as [20]
Cites
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129 · see citing works
MacDonald, M. R., Eurich, D. T., Majumdar, S. R., Lewsey, J. D., Bhagra, S., Jhund, P. S., Petrie, M. C., McMurray, J. J. V., Petrie, J. R., & McAlister, F. A. (2010) · Diabetes Care · doi:10.2337/dc09-2227 · Cited by 149 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Weiss, T., Yang, L., Carr, R. D., Pal, S., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002517 · Cited by 152 · see citing works
Weiss, T., Carr, R. D., Pal, S., Yang, L., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s277676 · Cited by 126 · see citing works
Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
Levin, P. A., Nguyen, H., Wittbrodt, E., & Kim, S. C. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s130834 · Cited by 107 · see citing works
- Authors
- Nyeland, M. E., Ploug, U. J., Richards, A., Garcia Alvarez, L., Demuth, D., Muthutantri, A., Skovgaard, R., & Evans, M.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Real‐World Evidence Solutions and Health Economics & Outcomes Research IMS Health London UK
- University Hospital of Wales (GB)
- Corresponding author
- Nyeland, M. E.
- Venue
- International Journal of Clinical Practice
- Publisher
- Wiley
- Published
- 2014-10-10
- Volume
- 69
- Issue
- 3
- Pages
- 281-291
- ISSN
- 1368-5031 (ISSN-L)
- 1742-1241
- OpenAlex
- W1990162248
- Cited by
- 21
- References
- 2
- Citations by year
- 2025: 2 · 2022: 2 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 4 · 2016: 6 · 2015: 2
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- International Journal of Clinical Practice (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- liraglutide, sitagliptin, type 2 diabetes, glycemic control, HbA1c, weight loss, body mass index, systolic blood pressure, real-world effectiveness, primary care, GLP-1 receptor agonists, DPP-4 inhibitors, Clinical Practice Research Datalink
- MeSH terms
- Sitagliptin Phosphate, Liraglutide, Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Follow-Up Studies, United Kingdom, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Primary Health Care, Retrospective Studies, Prevalence, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
